Karen Seibert

24.3k total citations · 9 hit papers
99 papers, 18.8k citations indexed

About

Karen Seibert is a scholar working on Pharmacology, Genetics and Organic Chemistry. According to data from OpenAlex, Karen Seibert has authored 99 papers receiving a total of 18.8k indexed citations (citations by other indexed papers that have themselves been cited), including 81 papers in Pharmacology, 45 papers in Genetics and 32 papers in Organic Chemistry. Recurrent topics in Karen Seibert's work include Inflammatory mediators and NSAID effects (81 papers), Estrogen and related hormone effects (45 papers) and Eicosanoids and Hypertension Pharmacology (23 papers). Karen Seibert is often cited by papers focused on Inflammatory mediators and NSAID effects (81 papers), Estrogen and related hormone effects (45 papers) and Eicosanoids and Hypertension Pharmacology (23 papers). Karen Seibert collaborates with scholars based in United States, Canada and Australia. Karen Seibert's co-authors include Jaime L. Masferrer, Peter C. Isakson, Philip Needleman, Ben S. Zweifel, Scott D. Hauser, K. Leahy, Carol M. Koboldt, Chinthalapally V. Rao, Mark G. Currie and James K. Gierse and has published in prestigious journals such as Nature, Science and Proceedings of the National Academy of Sciences.

In The Last Decade

Karen Seibert

97 papers receiving 18.0k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents

1996 1.6k citations Ravi G. Kurumbail, James K. Gierse et al. profile →
Pharmacological and biochemical demonstration of the role of cyclooxygenase 2 in inflammation and pain.

1994 1.3k citations Karen Seibert, K. Leahy et al. profile →
Nitric oxide activates cyclooxygenase enzymes.

1993 1.2k citations Daniela Salvemini, Jaime L. Masferrer et al. profile →
Selective inhibition of inducible cyclooxygenase 2 in vivo is antiinflammatory and nonulcerogenic.

1994 1.1k citations Jaime L. Masferrer, Ben S. Zweifel et al. profile →
Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors.

2000 1.1k citations Jaime L. Masferrer, K. Leahy et al. PubMed profile →
Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis.

1998 809 citations Chinthalapally V. Rao, Karen Seibert et al. PubMed profile →
The induction and suppression of prostaglandin H2 synthase (cyclooxygenase) in human monocytes.

1990 784 citations Jaime L. Masferrer, Karen Seibert et al. Journal of Biological Chemistry profile →
Pharmacological analysis of cyclooxygenase-1 in inflammation

1998 713 citations Yan Zhang, Carol M. Koboldt et al. profile →
4-[5-Methyl-3-phenylisoxazol-4-yl]- benzenesulfonamide, Valdecoxib: A Potent and Selective Inhibitor of COX-2

2000 569 citations John J. Talley, David Brown et al. profile →

Peers

Countries citing papers authored by Karen Seibert

Since Specialization

Citations

This map shows the geographic impact of Karen Seibert's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Karen Seibert with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Karen Seibert more than expected).

Fields of papers citing papers by Karen Seibert

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Karen Seibert. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Karen Seibert. The network helps show where Karen Seibert may publish in the future.

Co-authorship network of co-authors of Karen Seibert

This figure shows the co-authorship network connecting the top 25 collaborators of Karen Seibert. A scholar is included among the top collaborators of Karen Seibert based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Karen Seibert. Karen Seibert is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	The novel benzopyran class of selective cyclooxygenase-2 inhibitors-part I: The first clinical candidate 2010 ·Bioorganic & Medicinal Chemistry Letters ·Jane L. Wang, (unknown), James R. Kiefer, Ravi G. Kurumbail, Jennifer L. Pawlitz, David Brown, (unknown), Matthew J. Graneto, Karen Seibert, John J. Talley	43
2	Evaluation of COX-1/COX-2 selectivity and potency of a new class of COX-2 inhibitors 2008 ·European Journal of Pharmacology ·James K. Gierse, Maureen A. Nickols, K. Leahy, (unknown), Yan Zhang, Luz Cortes-Burgos, (unknown), Karen Seibert, Jaime L. Masferrer	28
3	Valdecoxib: Assessment of Cyclooxygenase-2 Potency and Selectivity 2005 ·Journal of Pharmacology and Experimental Therapeutics ·James K. Gierse, Yan Zhang, William F. Hood, Mark C. Walker, Jennifer S. Trigg, Timothy J. Maziasz, Carol M. Koboldt, Jerry Muhammad, Ben S. Zweifel, Jaime L. Masferrer, Peter C. Isakson, Karen Seibert	72
4	Dose-response effects of the COX-2 inhibitor, celecoxib, on the chemoprevention of mammary carcinogenesis. 2002 ·PubMed ·Hussein Abou‐Issa, Galal A. Alshafie, Karen Seibert, Alane Koki, Jaime L. Masferrer, Randall E. Harris	60
5	Pharmacology of Celecoxib in Rat Brain after Kainate Administration 2002 ·Journal of Pharmacology and Experimental Therapeutics ·Paola Ciceri, Yan Zhang, (unknown), K. Leahy, (unknown), Walter G. Smith, Karen Seibert, Peter C. Isakson	86
6	Characterization of cyclooxygenase-2 (COX-2) during tumorigenesis in human epithelial cancers: evidence for potential clinical utility of COX-2 inhibitors in epithelial cancers 2002 ·Prostaglandins Leukotrienes and Essential Fatty Acids ·Alane Koki, Nasir Khan, B. Mark Woerner, Karen Seibert, (unknown), Andrew J. Dannenberg, Robert A. Soslow, Jaime L. Masferrer	42
7	A three-step kinetic mechanism for selective inhibition of cyclo-oxygenase-2 by diarylheterocyclic inhibitors 2001 ·Biochemical Journal ·Mark C. Walker, Ravi G. Kurumbail, James R. Kiefer, Kirby T. Moreland, Carol M. Koboldt, Peter C. Isakson, Karen Seibert, James K. Gierse	69
8	Aspirin-like molecules that covalently inactivate cyclooxygenase-2 1999 ·Amit S. Kalgutkar, Brenda C. Crews, Scott W. Rowlinson, (unknown), Karen Seibert, L.J. Marnett, A. J. Kresge	50
9	4,5-Diaryloxazole inhibitors of cyclooxygenase-2 (COX-2) 1999 ·Medicinal Research Reviews ·John J. Talley, Stephen R. Bertenshaw, David Brown, Jeffery S. Carter, (unknown), Carol M. Koboldt, Jaime L. Masferrer, Bryan H. Norman, D. Joseph Rogier, Ben S. Zweifel, Karen Seibert	32
10	Distribution of Cox-1 and Cox-2 in Normal and Inflamed Tissues 1997 ·Advances in experimental medicine and biology ·Karen Seibert, Yan Zhang, K. Leahy, Scott D. Hauser, Jaime L. Masferrer, Peter C. Isakson	118
11	Pharmacological manipulation of cyclo‐oxygenase‐2 in the inflamed hydronephrotic kidney 1996 ·British Journal of Pharmacology ·Karen Seibert, Jaime L. Masferrer, P Needleman, Daniela Salvemini	32
12	Selective neutralization of prostaglandin E2 blocks inflammation, hyperalgesia, and interleukin 6 production in vivo. 1996 ·The Journal of Experimental Medicine ·Joseph P. Portanova, (unknown), Graham Anderson, Scott D. Hauser, Jaime L. Masferrer, Karen Seibert, S A Gregory, Peter C. Isakson	359
13	Evaluation of cyclooxygenase-2 inhibitor for potential chemopreventive properties in colon carcinogenesis. 1996 ·PubMed ·Bandaru S. Reddy, Chinthalapally V. Rao, Karen Seibert	372
14	A Single Amino Acid Difference between Cyclooxygenase-1 (COX-1) and −2 (COX-2) Reverses the Selectivity of COX-2 Specific Inhibitors 1996 ·Journal of Biological Chemistry ·James K. Gierse, Joseph J. McDonald, Scott D. Hauser, Shaukat H. Rangwala, Carol M. Koboldt, Karen Seibert	331
15	Novel 1,2-diarylcyclopentenes are selective, potent, and orally active cyclooxygenase inhibitors 1995 ·Medicinal Chemistry Research ·David B. Reitz, James J. Li, (unknown), Emily J. Reinhard, (unknown), (unknown), Joe Collins, Danny J. Garland, Karen Seibert, Carol M. Koboldt, Susan A. Gregory, Amy W. Veenhuizen, Yan Zhang, Peter C. Isakson	10
16	Mediation of Inflammation by Cyclooxygenase-2 1995 ·Birkhäuser Basel eBooks ·Karen Seibert, Jaime L. Masferrer, Yan Zhang, Susan A. Gregory, Gary L. Olson, Scott D. Hauser, K. Leahy, William J. Perkins, Peter C. Isakson	121
17	Discovery of a better aspirin. 1995 ·PubMed ·Peter C. Isakson, Karen Seibert, Jaime L. Masferrer, Daniela Salvemini, (unknown), Philip Needleman	21
18	NITRIC OXIDE ACTIVATES THE CYCLOOXYGENASE PATHWAY IN INFLAMMATION 1995 ·American Journal of Therapeutics ·Daniela Salvemini, Karen Seibert, Jaime L. Masferrer, Steven L. Settle, Mark G. Currie, Philip Needleman	22
19	Cytokine Regulation of Eicosanoid Generation 1994 ·Annals of the New York Academy of Sciences ·Peter C. Isakson, Scott D. Hauser, Yan Zhang, K. Leahy, Jaime L. Masferrer, Karen Seibert	5
20	Post-translational processing and secretory pathway of human atriopeptin in rat pheochromocytoma cells 1991 ·Biochemical and Biophysical Research Communications ·Shozo Shiono, Nobuhiko Suganuma, (unknown), Irving Boime, Karen Seibert, Kazuwa Nakao, Masashi Mukoyama, Hiroo Imura, Philip Needleman	5

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact